Focus
Emergency Use Authorization
FDA Revises Emergency Use of Paxlovid
The revision is a step toward finalizing the transition from Paxlovid’s emergency use authorization to its new drug application label, initiated in late 2023.
Researchers Find Pfizer Excluded Clinical Trial Deaths From FDA COVID Vaccine EUA Request
An accurate reporting by Pfizer would have shown equal numbers of clinical trial deaths in the vaccine and placebo groups and thus, no benefit of vaccination.
